Search

Displaying results 2721 - 2730 of 6951 in total
  1. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and

  2. Drug

    Luteinizing hormone

    go.drugbank.com/drugs/DB14741
    ApprovedInvestigational

    Mixtures: MENOGON 75 IU Powder and Solvent for solution for Injection
  3. Drug

    Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

    go.drugbank.com/drugs/DB10994
    ApprovedWithdrawn

    Mixtures: CERVARIX SUSPENSION FOR INJECTION
  4. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists
  6. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.

  7. Drug

    Bimatoprost

    go.drugbank.com/drugs/DB00905
    ApprovedInvestigational

    [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug

  8. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    [A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.

    Categories: Antihypertensive Agents Indicated for Hypertension, Mineralocorticoid Receptor Antagonists
  9. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

  10. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation. … The main soy isoflavones are mostly present in glycosylated forms and include [DB01645], [DB13182], and glycitein, which accounts for approximately 50%, 40%, and 10%, respectively, of the total soybean